{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T02:05:17Z","timestamp":1773021917695,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.clinthera.2009.10.008","type":"journal-article","created":{"date-parts":[[2009,11,17]],"date-time":"2009-11-17T09:48:11Z","timestamp":1258451291000},"page":"2206-2214","source":"Crossref","is-referenced-by-count":34,"title":["Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: A phase I\u2013II, open-label trial"],"prefix":"10.1016","volume":"31","author":[{"given":"Timothy","family":"Vollmer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Herbert R.","family":"Henney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.10.008_bib1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.pharmthera.2005.10.006","article-title":"Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatment","volume":"111","author":"Judge","year":"2006","journal-title":"Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2009.10.008_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0014-2999(77)90176-5","article-title":"The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals","volume":"42","author":"Lundh","year":"1977","journal-title":"Eur J Pharmacol."},{"key":"10.1016\/j.clinthera.2009.10.008_bib3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/0006-8993(85)91049-2","article-title":"4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve","volume":"328","author":"Targ","year":"1985","journal-title":"Brain Res."},{"key":"10.1016\/j.clinthera.2009.10.008_bib4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1085\/jgp.102.5.797","article-title":"Gating-dependent mechanism of 4-aminopyridine block in two related potassium channels","volume":"102","author":"Kirsch","year":"1993","journal-title":"J Gen Physiol."},{"key":"10.1016\/j.clinthera.2009.10.008_bib5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0306-4522(96)00477-0","article-title":"Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord","volume":"77","author":"Shi","year":"1997","journal-title":"Neuroscience."},{"key":"10.1016\/j.clinthera.2009.10.008_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/neu.1993.10.1","article-title":"4-Aminopyridine in chronic spinal cord injury: A controlled, double-blind, crossover study in eight patients","volume":"10","author":"Hansebout","year":"1993","journal-title":"J Neurotrauma."},{"key":"10.1016\/j.clinthera.2009.10.008_bib7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/sj.sc.3100559","article-title":"Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: Three cases","volume":"36","author":"Potter","year":"1998","journal-title":"Spinal Cord."},{"key":"10.1016\/j.clinthera.2009.10.008_bib8","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1592\/phco.19.9.713.31540","article-title":"Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: A long-term, controlled trial","volume":"19","author":"Segal","year":"1999","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.clinthera.2009.10.008_bib9","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/00912700022008982","article-title":"Absorption characteristics of sustained-release 4-aminopyridine (fam pridine SR) in patients with chronic spinal cord injury","volume":"40","author":"Segal","year":"2000","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2009.10.008_bib10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s004150170111","article-title":"Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury","volume":"248","author":"van der Bruggen","year":"2001","journal-title":"J Neurol."},{"key":"10.1016\/j.clinthera.2009.10.008_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/sj.sc.3101947","article-title":"Phase 2 trial of sustained-release fampridine in chronic spinal cord injury","volume":"45","author":"Cardenas","year":"2007","journal-title":"Spinal Cord."},{"key":"10.1016\/j.clinthera.2009.10.008_bib12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/archneur.1994.00540150090022","article-title":"4-Aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety","volume":"51","author":"Polman","year":"1994","journal-title":"Arch Neurol."},{"key":"10.1016\/j.clinthera.2009.10.008_bib13","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1212\/WNL.48.4.817","article-title":"Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis","volume":"48","author":"Schwid","year":"1997","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2009.10.008_bib14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1352458506069538","article-title":"Fampridine-SR in multiple sclerosis: A randomized, double-blind, placebo-controlled, dose-ranging study","volume":"13","author":"Goodman","year":"2007","journal-title":"Mult Scler."},{"key":"10.1016\/j.clinthera.2009.10.008_bib15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0091270003251388","article-title":"Pharmacokinetics of an immediaterelease oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury","volume":"43","author":"Hayes","year":"2003","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2009.10.008_bib16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/bja\/53.6.567","article-title":"Pharmacokinetics of 4-aminopyridine in human volunteers. A preliminary study using a new GLC method for its estimation","volume":"53","author":"Evenhuis","year":"1981","journal-title":"Br J Anaesth."},{"key":"10.1016\/j.clinthera.2009.10.008_bib17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/clpt.1982.82","article-title":"4-Aminopyridine kinetics","volume":"31","author":"Uges","year":"1982","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2009.10.008_bib18","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.44.6.1054","article-title":"The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial","volume":"44","author":"Bever","year":"1994","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2009.10.008_bib19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3109\/15563658008989978","article-title":"Poisoning with 4-aminopyridine: Report of three cases","volume":"16","author":"Spyker","year":"1980","journal-title":"Clin Toxicol."},{"key":"10.1016\/j.clinthera.2009.10.008_bib20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/15563659409011063","article-title":"Characterization of 4-aminopyridine in overdose","volume":"32","author":"Stork","year":"1994","journal-title":"J Toxicol Clin Toxicol."},{"key":"10.1016\/j.clinthera.2009.10.008_bib21","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0196-0644(96)70277-9","article-title":"Atypical presentation of 4-aminopyridine overdose","volume":"27","author":"Pickett","year":"1996","journal-title":"Ann Emerg Med."},{"key":"10.1016\/j.clinthera.2009.10.008_bib22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jemermed.2005.04.020","article-title":"An unusual case of 4-aminopyridine toxicity","volume":"30","author":"Johnson","year":"2006","journal-title":"J Emerg Med."},{"key":"10.1016\/j.clinthera.2009.10.008_bib24","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1212\/01.wnl.0000339380.23073.58","article-title":"4-Aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis","volume":"71","author":"Burton","year":"2008","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2009.10.008_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0003-9993(03)00651-8","article-title":"Pharmacokinetics and safety of multiple oral doses of sustainedrelease 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury","volume":"85","author":"Hayes","year":"2004","journal-title":"Arch Phys Med Rehabil."},{"key":"10.1016\/j.clinthera.2009.10.008_bib26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: Guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Ann Neurol."},{"key":"10.1016\/j.clinthera.2009.10.008_bib27","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.wnl.0000326213.89576.0e","article-title":"Dose comparison trial of sustained-release fampridine in multiple sclerosis","volume":"71","author":"Goodman","year":"2008","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2009.10.008_bib28","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","article-title":"Sustainedrelease oral fampridine in multiple sclerosis: A randomised, doubleblind, controlled trial","volume":"373","author":"Goodman","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2009.10.008_bib29","first-page":"2667","article-title":"Severe poisoning by 4-aminopyridine in a body builder [in Dutch]","volume":"139","author":"Smeets","year":"1995","journal-title":"Ned Tijdschr Geneeskd."},{"key":"10.1016\/j.clinthera.2009.10.008_bib30","first-page":"473","article-title":"Human botulism caused by Clostridium botulinum type E: The Birmingham outbreak","volume":"48","author":"Ball","year":"1979","journal-title":"QJ Med."},{"key":"10.1016\/j.clinthera.2009.10.008_bib31","series-title":"Handbook of Basic Pharmacokinetics\u2014Including Clinical Applications","author":"Ritschell","year":"1992"},{"key":"10.1016\/j.clinthera.2009.10.008_bib33","series-title":"Primer of Biostatistics","author":"Glantz","year":"1981"},{"key":"10.1016\/j.clinthera.2009.10.008_bib34","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clinthera.2009.02.004","article-title":"Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers","volume":"31","author":"Blight","year":"2009","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2009.10.008_bib35","unstructured":"Smith W, Swan S, Marbury T, Henney HR III. Single-dose pharmacokinetics of 4-aminopyridine slow release in healthy volunteers and renally impaired adults. J Clin Pharmacol. In press."},{"key":"10.1016\/j.clinthera.2009.10.008_bib36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00002826-200307000-00007","article-title":"Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury","volume":"26","author":"Hayes","year":"2003","journal-title":"Clin Neuropharmacol."},{"key":"10.1016\/j.clinthera.2009.10.008_bib37","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2009.10.008_bib38","first-page":"90","article-title":"Pharmacokinetics tricks and traps: Flip-flop models","volume":"1","author":"Boxenbaum","year":"1998","journal-title":"J Pharm Pharm Sci."},{"key":"10.1016\/j.clinthera.2009.10.008_bib39","series-title":"Multiple Sclerosis: Diagnosis, Medical Management, and Rehabilitation","year":"2000"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809003658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809003658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,15]],"date-time":"2018-12-15T05:50:58Z","timestamp":1544853058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809003658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0149291809003658"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.10.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}